<p>(A) Risk of progression at a time step of 1.5 years given no progression at earlier time steps (<i>hazard</i> of progression). All transitions have decreasing hazard, reflecting the odds ratios <1 in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0020104#pone-0020104-t004" target="_blank">Table 4</a> for years in stage. For the transition from stage 2 to 3, the estimated hazard of progression is 0.55 for the first step and 0 at all later times; this is not shown to avoid compression of the vertical scale for the other transitions. (b) Cumulative risk of progression. The cumulative risk in the first time step is equal to the hazard; at later time steps, it is equal to the previous cumulative risk plus the current ha...
<p>The figure shows time trends of the CD4 slope (A) and the viral setpoint (B) in the heterosexual ...
a<p>Chronic illness includes heart disease, stroke, or cancer (except non-melanoma skin cancer).</p>...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
a<p>Odds ratios indicate the estimated effects of the predictors on the risk of progression to the n...
<p>Background mortality probabilities were derived from the national age-specific mortality rates fo...
<p>The hazard ratio was calculated by using the Cox proportional hazard model.</p><p>AFP = α-fetopro...
The horizontal axis denotes the timeline in years, while the vertical axis represents the risk value...
When a risk factor influences the intermediary but not progression to the endpoint, it has been show...
Hazard ratios (95% confidence interval) of progression to end-stage kidney disease (ESKD) and all-ca...
<p>A: Cohort-sequential model estimates for morbidity. B: Hockey stick regression model estimates fo...
Biomarkers play a key role in the monitoring of disease progression. The time taken for an individua...
The horizontal axis denotes the timeline in years, while the vertical axis represents the risk value...
Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is...
<p>Adjusted hazard ratios for the occurrence of hepatocellular carcinoma (HCC) during the follow-up ...
BackgroundFibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but a...
<p>The figure shows time trends of the CD4 slope (A) and the viral setpoint (B) in the heterosexual ...
a<p>Chronic illness includes heart disease, stroke, or cancer (except non-melanoma skin cancer).</p>...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
a<p>Odds ratios indicate the estimated effects of the predictors on the risk of progression to the n...
<p>Background mortality probabilities were derived from the national age-specific mortality rates fo...
<p>The hazard ratio was calculated by using the Cox proportional hazard model.</p><p>AFP = α-fetopro...
The horizontal axis denotes the timeline in years, while the vertical axis represents the risk value...
When a risk factor influences the intermediary but not progression to the endpoint, it has been show...
Hazard ratios (95% confidence interval) of progression to end-stage kidney disease (ESKD) and all-ca...
<p>A: Cohort-sequential model estimates for morbidity. B: Hockey stick regression model estimates fo...
Biomarkers play a key role in the monitoring of disease progression. The time taken for an individua...
The horizontal axis denotes the timeline in years, while the vertical axis represents the risk value...
Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is...
<p>Adjusted hazard ratios for the occurrence of hepatocellular carcinoma (HCC) during the follow-up ...
BackgroundFibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but a...
<p>The figure shows time trends of the CD4 slope (A) and the viral setpoint (B) in the heterosexual ...
a<p>Chronic illness includes heart disease, stroke, or cancer (except non-melanoma skin cancer).</p>...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...